Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 17:2022:9096940.
doi: 10.1155/2022/9096940. eCollection 2022.

The Effect and Safety of Xuefu Zhuoyue Prescription for Coronary Heart Disease: An Overview of Systematic Reviews and Meta-Analyses

Hongshuo Shi  1 , Zunhao Tang  1 , Ting Liu  2 , Xuecheng Zhang  3   4 , Yao Wang  1 , Jie Li  1 , Chengda Dong  5 , Wenqiang Chen  1 , Ruirui Hou  5 , Guomin Si  2 , Yan Liu  6
Affiliations
Review

The Effect and Safety of Xuefu Zhuoyue Prescription for Coronary Heart Disease: An Overview of Systematic Reviews and Meta-Analyses

Hongshuo Shi et al. Evid Based Complement Alternat Med. .

Abstract

Background: In China, the traditional Chinese medicine compound Xuefu Zhuoyue prescription (XFZY) has been widely used in the therapy of coronary heart disease (CHD). Currently, several systematic reviews (SRs)/meta-analyses (MAs) of XFZY for the treatment of CHD have been published. This overview aims to evaluate the existing SRs/MAs and provide a scientific basis for evaluating the efficacy and safety of XFZY for the therapy of CHD.

Methods: The SRs/MAs of XFZY for the treatment of CHD were obtained from 7 electronic databases with the search date set at March 7, 2022. Two researchers independently assessed the methodological quality, reporting quality, and evidence quality of the included SRs/MAs using the following tools: the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2), the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA 2020), and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.

Results: A total of 11 SRs/MAs were included in this overview. All SRs/MAs assessed by means of AMSTAR-2 had more than one critical defect, so all SRs/MAs were rated low. Regarding the assessment of reporting quality, the results of PRISMA 2020 showed that none of the SRs/MAs were fully reported. In addition, the results of the GRADE assessment of the quality of evidence indicated that only one outcome was rated as high quality across all SRs/MAs.

Conclusion: Current evidence suggests that XFZY is effective and safe for the management of patients with CHD. However, the high risk of bias of the original clinical studies and the low quality of the SRs/MAs reduced the reliability of the results.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Figures

Figure 1
Figure 1
The flowchart of the screening process.
See this image and copyright information in PMC

References

    1. Akhabue E., Thiboutot J., Cheng J. W., et al. New and emerging risk factors for coronary heart disease. The American Journal of the Medical Sciences . 2014;347(2):151–158. doi: 10.1097/MAJ.0b013e31828aab45. - DOI - PubMed
    1. GBD 2017 Causes of Death Collaborators. 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet . 2018;392(10159):1736–1788. doi: 10.1016/S0140-6736(18)32203-7. - DOI - PMC - PubMed
    1. Graziano R., Valeriana S. Atherosclerosis: from biology to pharmacological treatment. Journal of Geriatric Cardiology . 2012;9(3):305–317. doi: 10.3724/SP.J.1263.2012.02132. - DOI - PMC - PubMed
    1. Hagström E., Norlund F., Stebbins A., et al. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. Journal of Internal Medicine . 2018;283(1):83–92. doi: 10.1111/joim.12692. - DOI - PubMed
    1. Tian Y., Deng P., Li B., et al. Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance. Reviews in Cardiovascular Medicine . 2019;20(1):27–33. doi: 10.31083/j.rcm.2019.01.53. - DOI - PubMed

LinkOut - more resources